多発性骨髄腫の世界市場-2023年～2030年

市場概要

多発性骨髄腫の世界市場は、2022年に202億米ドルに達し、2030年には313億米ドルまで成長すると予測されています。世界の多発性骨髄腫市場は、2023年から2030年の予測期間中にCAGR 5.8%を示すと予測されています。

多発性骨髄腫の症例の増加、危険因子の有病率の増加、認知度の向上、資金提供の取り組み、検索活動の増加、有利な償還政策、製品の上市、製品認可、提携、買収、連合、拡大などの市場開拓などが、予測期間における世界の多発性骨髄腫市場の成長を後押しすると予想されます。この市場における主要な市場プレイヤーには、Sanofi S.A.、武田薬品工業、Bristol-Myers Squibb Company、GlaxoSmithKlineなどが含まれます。

市場力学

製品承認の増加が多発性骨髄腫市場の成長を牽引

製品承認の増加は、予測期間における世界の多発性骨髄腫市場の成長を促進します。例えば、2022年10月25日、食品医薬品局は多発性骨髄腫の一部の患者を治療するためにテクリスタマブ（Tecvayli）に早期承認（accelerated clearance）を与えました。この認可は、MajesTEC-1試験の結果に基づくもので、最低4ラインの初期治療後に再発した成人の多発性骨髄腫が対象です。

世界多発性骨髄腫市場に成長機会をもたらすと期待される認知度向上への取り組み増加

認知を広める取り組みの増加は、今後数年間、世界の多発性骨髄腫市場に有利な成長機会をもたらすと期待されています。例えば、2023年 2月には、多発性骨髄腫研究財団（MMRF）と、がん臨床試験への個人のアクセスを強化することに集中した非営利団体であるLazarex Cancer Foundationが、多発性骨髄腫がん患者の臨床試験へのさらなる偏りのないアクセスを維持するために協力関係を結びました。

予測期間中、治療費の高さが世界の多発性骨髄腫市場の妨げになると予測されます

治療費の高さは、予測期間における世界の多発性骨髄腫市場の成長を妨げると予測されています。例えば、ある分析では、保険適用前の多発性骨髄腫患者に対する多剤併用療法の全費用は、約74,000ドルから最高で256,000ドルでした。

COVID-19影響分析

COVID-19の大流行と世界各国での封鎖により、あらゆる業種の企業の財務状況が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ戦争の影響分析

ロシアとウクライナの抗争は、世界の多発性骨髄腫市場には中程度の影響しか及ぼさないと考えられています。しかし、ロシア軍からの襲撃に耐え続けるウクライナの診療所は、死亡者数の増加と特定の医療補助に押されています。

あらゆる種類の薬が不足しています。ここでも、基本材料の輸出入が、予測期間中の世界の多発性骨髄腫市場の成長に与える影響は小さいと予測されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 製品認可の増加
    • 普及率の増加
  • 抑制要因
    • 高コスト
  • 機会
    • 調査投資の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 治療タイプ別

• 免疫療法
• 化学療法
• 放射線療法
• その他

第8章 エンドユーザー別

• 病院
• がんセンター
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Takeda Pharmaceutical Company Limited
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Amgen Inc.
• Sanofi S.A.
• Novartis International AG
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Johnson and Johnson, Inc.（Janssen Pharmaceuticals）
• Bristol-Myers Squibb Company
• Karyopharm Therapeutics Inc.
• Ono Pharmaceutical Co., Ltd

第12章 付録

Market Overview

The Global Multiple Myeloma Market reached US$ 20.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 31.3 billion by 2030. The Global Multiple Myeloma Market is expected to exhibit a CAGR of 5.8% during the forecast period 2023-2030.

The increasing cases of multiple myeloma, increase in the prevalence of risk factors, growing awareness, funding initiatives, increasing search activities, favorable reimbursement policies, and market developments such as product launches, product authorizations, alliances, acquisitions, coalitions, and expansion among others are expected to boost the global Multiple Myeloma market growth in the forecast period. The key market players in this market include Sanofi S.A., Takeda Pharmaceutical Company, Bristol-Myers Squibb Company, and GlaxoSmithKline among others.

Market Dynamics

Increasing Product Approvals Drive The Growth Of The Multiple Myeloma Market.

Increasing product approvals will drive the global multiple myeloma market growth in the forecast period. For instance, on October 25, 2022, the Food and Drug Administration granted accelerated clearance to teclistamab (Tecvayli) to treat some individuals with multiple myeloma. The authorization, founded on the outcomes of the MajesTEC-1 trial, is for adults with multiple myeloma that has come around after a minimum of four initial lines of therapy.

The Increasing Efforts To Spread Awareness Are Expected To Present The Global Multiple Myeloma Market With Growth Opportunities.

The increasing awareness initiatives are expected to present the global multiple myeloma market with lucrative growth opportunities in the upcoming years. For instnace, in February 2023, the Multiple Myeloma Research Foundation (MMRF) and the Lazarex Cancer Foundation, a non-profit association concentrated on enhancing individuals' access to cancer clinical investigations, formed a collaboration to sustain additional unbiased access to clinical trials for multiple myeloma cancer individuals.

The High Cost of Treatment Is Estimated To Hamper The Global Multiple Myeloma Market During The Forecast Period.

The high cost of treatment is estimated to hamper the global multiple myeloma market growth in the forecast period. For instance, in one analysis, the entire expense of a multi-medication therapy for individuals with multiple myeloma before insurance varied from around $74,000 to as high as $256,000.

COVID-19 Impact Analysis.

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis.

The Russia-Ukraine brawl is considered to carry a moderate mark on the global multiple myeloma market as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids.

There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of basic materials are predicted to have a small influence on the global multiple myeloma market growth in the forecast period.

Segment Analysis

The Global Multiple Myeloma Market is segmented based on treatment type, end-user, and region.

Owing To The Increasing Research Investments, The Immunotherapy Segment Is Estimated To Hold About 28% Of The Global Market Share By 2030.

Owing to the increasing research investments in the immunotherapy treatment type, the segment is estimated to dominate the global market, holding about 28.6% of the total market share. For instance, in March 2022, the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, invested in Triumvira Immunologics (Triumvira), an Austin, TX-based clinical-stage biotech developing novel, targeted autologous and allogeneic T cell immunotherapies that co-opt the natural biology of T cells to treat solid tumors and blood cancers.

Geographical Analysis

Europe Estimated to Hold 26.6% of the Market Share Owing to the Growing Multiple Myeloma Prevalence in this Region.

Owing to the increasing product authorizations in Europe, the region is estimated to hold the second-largest global market share, accounting for around 29%. For instance, in July 2022, EMA instructed a conditional marketing authorization in the European Union (EU) for Tecvayli (teclistamab) for the therapy of grown-up individuals with relapsed and refractory multiple myeloma, who have obtained at a minimum of three previous treatments, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has declined from obtaining the latest therapy.

Also, in September 2022, the European Commission authorized Pepaxti (melphalan sulfenamide, also called melflufen), a drug by Oncopeptides to be employed in blend with dexamethasone, pushing it obtainable to adults with hard-to-treat multiple myeloma in Europe.

Competitive Landscape

The major global players in the multiple myeloma market include: Takeda Pharmaceutical Company Limited, Amgen Inc., Sanofi S.A., Novartis International AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Johnson and Johnson, Inc. (Janssen Pharmaceuticals), Bristol-Myers Squibb Company, Karyopharm Therapeutics Inc., and Ono Pharmaceutical Co., Ltd., among others.

Why Purchase the Report?

• To visualize the Global Multiple Myeloma Market segmentation based on treatment type, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous multiple myeloma market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Multiple Myeloma Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by End-user
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Product Approvals
    • 4.1.1.2. Growing Prevalence
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Research Investments
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Immunotherapy *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Chemotherapy
• 7.4. Radiation Therapy
• 7.5. Others

8. By End-user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 8.1.2. Market Attractiveness Index, By End-user
• 8.2. Hospitals *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cancer Centers
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. The U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. The U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Spain
    • 9.3.5.5. Italy
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan

Australia

• 9.5.5.4. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Takeda Pharmaceutical Company Limited*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Amgen Inc.
• 11.3. Sanofi S.A.
• 11.4. Novartis International AG
• 11.5. Teva Pharmaceutical Industries Ltd.
• 11.6. GlaxoSmithKline plc
• 11.7. Johnson and Johnson, Inc. (Janssen Pharmaceuticals)
• 11.8. Bristol-Myers Squibb Company
• 11.9. Karyopharm Therapeutics Inc.
• 11.10. Ono Pharmaceutical Co., Ltd

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us